Study shows Wegovy produces benefit for heart failure
Trial finds- Wegovy produces benefit for patients with heart failure
Wegovy produces benefit for patients with heart failure
In a recent article published by MedPage Today, Semaglutide 2.4 mg (Wegovy) led to clinically meaningful reductions in symptoms and weight among patients with obesity and heart failure with preserved ejection fraction (HFpEF), the STEP-HFpEF trial showed.
While the study was not designed to assess hard cardiovascular endpoints, where wegovy is supposed to cure the obesity problem in America, it did show that semaglutide improved Kansas City Cardiomyopathy Questionnaire (KCCQ) clinical summary scores to a greater extent after one year. The obesity problem in America is somewhat connected to heart failure and patients with heart failure, many of them actually value improvement in symptoms and reducing physical limitations as much or more as survival.
There are currently no approved treatments for the specific phenotype of combination HFpEF and the obesity problem in America. The prevalence of obesity problem in America, diabetes, and older age. The phenotype has a particularly high burden of physical limitations and poor quality of life.
Read Also:Weight-Loss Drug Wegovy Produces ‘Largest Benefit Ever Seen’ for Patients with Most Common form of Heart Failure, Trial Finds
The previous global clinical trial programs of agents such as SGLT2 inhibitors, sacubitril-valsartan [Entresto], and spironolactone for heart failure with preserved ejection fraction showed only modest changes in KCCQ scores (ranging from 0.5 to 2.3 points),” the study authors noted in their paper.
Given the obesity problem in America, Edward Fry, MD, of Ascension St. Vincent Heart Center in Indianapolis, and immediate past president of the American College of Cardiology, told MedPage Todaythat STEP-HFpEF is a wake-up call to non-cardiologists and primary care physicians, by whom many of these patients, and the obesity problem in America are getting their care, and noted that GLP-1 receptor agonist treatment is a good choice for patients with the obesity problem in America and HFpEF.
With the obesity problem in America, the main issue now is access and coverage, Kosiborod said. Semaglutide was approved for long-term weight management-opens in a new tab or window in the obesity problem in America. Many people, including those who belong to the obesity problem in America are asking for it for non-heart failure, non-diabetic indications and it’s a lot of pressure on the supply.
Read Also:Colchicine Stumbles for Protecting the Heart From Thoracic Surgery
